Gujarat Themis Biosyn Fair Value
Gujarat Themis Biosyn (GUJTHEM) average fair value is ₹404.59 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹389.35 (+3.91%), fair value range ₹62.8–₹1324.0. For live price and a broader fundamental view, visit Gujarat Themis Biosyn share price today.
Fair Value Analysis Export
GUJTHEM Fair Value vs Current Price — Valuation Summary
GUJTHEM average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). See GUJTHEM price to book ratio to compare market price against book value per share.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
GUJTHEM Fair Value Analysis — Data Sources & Coverage
Gujarat Themis Biosyn financial data sources, valuation methods applied and sector benchmarks used. Also explore GUJTHEM share price data to track price trends across different timeframes.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
GUJTHEM vs Healthcare Sector Peers — P/E, P/B & Market Cap
Gujarat Themis Biosyn P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Auro Laboratories | AUROLAB | 91.49 | 3.91 | ₹165 |
| Sun Pharmaceutical | SUNPHARMA | 41.43 | 5.83 | ₹442,581 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.